$Evaluating the antifracture efficacy of bisphosphonates.$

Evaluating the antifracture efficacy of bisphosphonates.

Oral bisphosphonate dosing schedules have evolved from the original daily regimens to weekly (alendronate and risedronate) and monthly (risedronate and ibandronate) regimens. Intravenous (i.v.) bisphosphonates are administered less frequently-quarterly ibandronate injection and yearly zoledronic aci...

Podrobná bibliografie
Hlavní autoři:	Pazianas, M, Epstein, S, Zaidi, M
Médium:	Journal article
Jazyk:	English
Vydáno:	2009

Podobné jednotky

Antifracture agents for prostate cancer patients on androgen deprivation therapy
Autor: Bhupendra P Singh, a další
Vydáno: (2010-01-01)

The sequential antifracturative treatment: a meta-analysis of randomized clinical trials
Autor: Angelo Fassio, a další
Vydáno: (2024-04-01)

Safety of bisphosphonates.
Autor: Pazianas, M, a další
Vydáno: (2011)

Bisphosphonates and bone quality.
Autor: Pazianas, M, a další
Vydáno: (2014)

Atrial fibrillation and bisphosphonate therapy.
Autor: Pazianas, M, a další
Vydáno: (2010)

Potential therapeutic effects of oral bisphosphonates on the intestine.
Autor: Pazianas, M, a další
Vydáno: (2011)

Safety issues with bisphosphonate therapy for osteoporosis.
Autor: Suresh, E, a další
Vydáno: (2014)

Are bisphosphonates associated with an increased risk of atypical femoral fractures as a class?
Autor: Pazianas, M
Vydáno: (2013)

Cardiovascular Safety of Antifracture Medications in Patients With Osteoporosis: A Narrative Review of Evidence From Randomized Studies
Autor: Alexander J Rodríguez, a další
Vydáno: (2022-06-01)

Cardiovascular Safety of Antifracture Medications in Patients With Osteoporosis: A Narrative Review of Evidence From Randomized Studies
Autor: Alexander J Rodríguez, a další
Vydáno: (2021-07-01)

Bisphosphonates and colon cancer: reply.
Autor: Pazianas, M, a další
Vydáno: (2013)

Bisphosphonates and colon cancer: Reply
Autor: Pazianas, M, a další
Vydáno: (2013)

Eliminating the need for fasting with oral administration of bisphosphonates.
Autor: Pazianas, M, a další
Vydáno: (2013)

Eliminating the need for fasting with oral administration of bisphosphonates
Autor: Pazianas M, a další
Vydáno: (2013-10-01)

NE‐58025: A bisphosphonate with a low hydroxyapatite binding affinity
Autor: Michael Pazianas
Vydáno: (2021-08-01)

Atrial fibrillation and the use of oral bisphosphonates.
Autor: Pazianas, M, a další
Vydáno: (2011)

Atrial fibrillation and the use of oral bisphosphonates
Autor: Michael Pazianas, a další
Vydáno: (2011-03-01)

Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis.
Autor: Pazianas, M, a další
Vydáno: (2010)

Findings of Danish study on risk of colon cancer in bisphosphonate users were misinterpreted.
Autor: Abrahamsen, B, a další
Vydáno: (2013)

NO ASSOCIATION BETWEEN THE USE OF ORAL BISPHOSPHONATES AND INCIDENCE OF ATRIAL FIBRILLATION
Autor: Pazianas, M, a další
Vydáno: (2010)

Comment on Tadrous et al.: comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis.
Autor: Pazianas, M, a další
Vydáno: (2014)

Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker.
Autor: Pazianas, M, a další
Vydáno: (2008)

Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker: Reply to Yarom and Elad
Autor: Pazianas, M, a další
Vydáno: (2008)

A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Autor: Pazianas, M, a další
Vydáno: (2007)

Impact of bisphosphonates in age-related macular degeneration: Retrospective cohort and nested case-control study
Autor: Garriga, C, a další
Vydáno: (2018)

Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate--Danish National Register Based Cohort Study.
Autor: Pazianas, M, a další
Vydáno: (2012)

Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications: cohort analysis using a national prescription database.
Autor: Pazianas, M, a další
Vydáno: (2013)

Oral bisphosphonate use and age-related macular degeneration: retrospective cohort and nested case-control study
Autor: Garriga, C, a další
Vydáno: (2018)

Impact of bisphosphonate use and age-related macular degeneration: retrospective cohort and nested case-control study
Autor: Garriga, C, a další
Vydáno: (2018)

Bisphosphonates and Age-Related Macular Degeneration: A Propensity-Matched Cohort and Nested Case-Control Analysis
Autor: Garriga, C, a další
Vydáno: (2017)

Bisphosphonates
Autor: Bishop, N, a další
Vydáno: (2013)

Bisphosphonates
Autor: Fırat Öztürk
Vydáno: (2009-04-01)

Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
Autor: Russell, R, a další
Vydáno: (2007)

Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
Autor: Russell, R, a další
Vydáno: (2007)

Safety and efficacy of bisphosphonates in thalassemia patients with osteopenia/osteoporosis
Autor: Sujata Sharma, a další
Vydáno: (2023-04-01)

Efficacy of Bisphosphonates for the Treatment of Osteoporosis in Patients with Multiple Sclerosis
Autor: İlke Coşkun Benlidayı, a další
Vydáno: (2015-08-01)

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.
Autor: Russell, R, a další
Vydáno: (2008)

Bisphosphonates: An update
Autor: Nalliappan Ganapathy, a další
Vydáno: (2012-01-01)

Bisphosphonates 2006
Autor: Russell, R
Vydáno: (2006)

Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.
Autor: Pazianas, M, a další
Vydáno: (2012)